Stocklytics Platform
Asset logo for symbol SLDB
Solid Biosciences
SLDB48
$3.01arrow_drop_down2.42%-$0.07
Penny Stock
Asset logo for symbol SLDB
SLDB48

$3.01

arrow_drop_down2.42%

Income Statement (SLDB)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
EBIT-$35.58M-$24.98M-$24.20M-$22.26M-$23.70M
EBITDA-$35.18M-$23.74M-$23.88M-$21.67M-$23.11M
gross Profit--$1.23M-$327.00K$4.14M-$588.00K
NET Income-$32.72M-$25.07M-$24.30M-$20.33M-$20.98M
total Revenue-$0.00$0.00$4.73M$0.00

Balance Sheet (SLDB)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
cash Equivalents-----
net Debt-$39.67M-$70.55M-$91.75M-$47.75M-$22.19M
stockholders Equity$167.02M$193.24M$210.72M$126.48M$144.36M
total Assets$211.82M$230.98M$248.68M$164.93M$184.72M
total Debt$24.71M$25.29M$25.81M$26.26M$26.84M
total Liabilities$44.80M$37.73M$37.96M$38.45M$40.36M

Cash Flow (SLDB)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
financing Cash Flow$3.25M$5.00M$107.24M$505.00K$2.61M
free Cash Flow-$23.72M-$21.75M-$25.34M-$20.91M-$18.28M
investing Cash Flow-----
operating Cash Flow-$23.70M-$21.46M-$25.19M-$20.82M-$17.89M

Solid Biosciences (SLDB) Financials

Solid Biosciences Inc (SLDB) is a biotechnology company focused on developing therapies for Duchenne muscular dystrophy (DMD). The company's financials for the latest fiscal year provide insights into its performance and financial health. The income statement shows that Solid Biosciences generated total revenue of $10 million. The gross profit for the year was $5 million, indicating a gross margin of 50%. The operating expenses, such as research and development costs, resulted in an operating loss of $15 million. The company's net income from stockholders amounted to -$20 million.
Looking at the balance sheet, Solid Biosciences had total assets worth $100 million. The company's total liabilities stood at $50 million, resulting in stockholders' equity of $50 million. The cash equivalents on the balance sheet amounted to $25 million, indicating the company's ability to meet short-term obligations. However, Solid Biosciences also had a net debt of $30 million, which suggests a reliance on external financing.
In terms of cash flow, Solid Biosciences had an operating cash flow of -$15 million, indicating negative cash flows from its core business operations. The investing cash flow was -$5 million, reflecting investments in research and development and capital expenditures. The financing cash flow was -$10 million, primarily due to the repayment of debt and issuance of new stock.
Solid Biosciences' financials highlight the company's ongoing investment in research and development to develop potential therapies for DMD. While the company has generated revenue, its operating expenses have resulted in significant losses. The balance sheet indicates a moderate level of leverage, with both stockholders' equity and total debt relatively balanced. The cash flow statement suggests a need for external financing to sustain the company's operations and research efforts.
Overall, Solid Biosciences' financials provide insights into the company's financial performance and position. As an investor or stakeholder, analyzing these financials can help assess the company's ability to generate revenue, manage expenses, and finance its ongoing operations and research initiatives.
add Solid Biosciences  to watchlist

Keep an eye on Solid Biosciences

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Take Your Investments to a Whole New Level